Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
When sterilizing medical devices, sterilization personnel rely on bioburden counts as part of determining and maintaining the sterilization process. In the following Q&A, Martell Winters, senior ...
Another driver contributing to the market growth is the growing emphasis on regulatory compliance. Regulatory authorities across the globe are imposing strict guidelines and regulations regarding ...
Reduced-volume bioburden testing represents a practical and defensible approach for low-volume, high-value cell and gene ...
The quality of water for pharmaceutical production (purified water, water for injection, and ultrapure water) is quantified and regulated through four parameters – total organic carbon (TOC), ...
A technician at Microtest performs bioburden testing using the aseptic technique. There are no commonly accepted levels of environmental bioburden. Industrial sterilization and contamination control ...
Richmond, Feb. 23, 2024 (GLOBE NEWSWIRE) -- According to MarketDigits, the Bioburden Testing Market was valued USD 1.2 Billion in 2023 and projected to reach USD 2.8 Billion by 2030, growing at a CAGR ...
WILMINGTON, Mass.—October 20, 2014 – Charles River Laboratories International, Inc. (NYSE: CRL) today introduced the PTS-Micro™ system, a new technology platform designed for rapid microbial burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results